Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte.
Am J Surg Pathol. 2022 Dec 1;46(12):1706-1715. doi: 10.1097/PAS.0000000000001967. Epub 2022 Aug 29.
NUT carcinoma (NC) is a rare subtype of squamous cell carcinoma defined by NUTM1 rearrangements encoding NUT fusion oncoproteins (the most frequent fusion partner being BRD4 ) that carries a very poor prognosis, with most patients dying in under 1 year. Only rare primary thyroid NCs have been reported. Here, we evaluated a series of 14 cases. The median patient age at diagnosis was 38 years (range: 17 to 72 y). Eight of 13 cases with slides available for review (62%) showed a morphology typical of NC, whereas 5 (38%) had a non-NC-like morphology, some of which had areas of cribriform or fused follicular architecture resembling a follicular cell-derived thyroid carcinoma. For cases with immunohistochemistry results, 85% (11/13) were positive for NUT on biopsy or resection, though staining was significantly decreased on resection specimens due to fixation; 55% (6/11) were positive for PAX8, and 54% (7/13) for TTF-1. Tumors with a non-NC-like morphology were all positive for PAX8 and TTF-1. The fusion partner was known in 12 cases: 9 (75%) cases had a NSD3-NUTM1 fusion, and 3 (25%) had a BRD4-NUTM1 fusion. For our cohort, the 2-year overall survival (OS) was 69%, and the 5-year OS was 58%. Patients with NC-like tumors had a significantly worse OS compared with that of patients with tumors with a non-NC-like morphology ( P =0.0462). Our study shows that NC of the thyroid can mimic other thyroid primaries, has a high rate of NSD3 - NUTM1 fusions, and an overall more protracted clinical course compared with nonthyroid primary NC.
NUT 癌(NC)是一种罕见的鳞状细胞癌亚型,由 NUTM1 重排定义,该重排编码 NUT 融合癌蛋白(最常见的融合伙伴是 BRD4),预后非常差,大多数患者在不到 1 年内死亡。仅有少数原发性甲状腺 NC 被报道。在此,我们评估了 14 例病例。诊断时中位患者年龄为 38 岁(范围:17 至 72 岁)。在有切片可供审阅的 13 例病例中(62%),8 例显示出典型的 NC 形态,而 5 例(38%)具有非 NC 样形态,其中一些具有类似于滤泡细胞衍生的甲状腺癌的筛状或融合滤泡结构的区域。对于具有免疫组织化学结果的病例,85%(11/13)在活检或切除标本中 NUT 阳性,但由于固定,在切除标本中染色明显减少;55%(6/11)PAX8 阳性,54%(7/13)TTF-1 阳性。具有非 NC 样形态的肿瘤均为 PAX8 和 TTF-1 阳性。融合伙伴在 12 例病例中可知:9 例(75%)病例存在 NSD3-NUTM1 融合,3 例(25%)病例存在 BRD4-NUTM1 融合。对于我们的队列,2 年总生存率(OS)为 69%,5 年 OS 为 58%。具有 NC 样肿瘤的患者与具有非 NC 样形态肿瘤的患者相比,OS 显著更差(P=0.0462)。我们的研究表明,甲状腺的 NC 可模拟其他甲状腺原发性肿瘤,具有高 NSD3-NUTM1 融合率,与非甲状腺原发性 NC 相比,总体临床病程更长。